• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

    12/6/24 7:00:00 AM ET
    $ASRT
    $BEAM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ASRT alert in real time by email

    CAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Sravan K. Emany as chief financial officer (CFO), effective December 19, 2024. Mr. Emany brings to Beam a breadth of global operational, commercial and financial experience with multinational public corporations and financial institutions. He most recently served as CFO and chief operating officer at Ironwood Pharmaceuticals, Inc.

    "Beam has built a strong financial position to advance our portfolio of genetic medicines, and Sravan has an exceptional background to lead our capital formation and allocation strategy going forward," said John Evans, chief executive officer of Beam. "With his deep understanding of value creation in the life sciences, along with significant operational and financial experience, Sravan is uniquely positioned to help guide Beam through its next phase of growth as we advance multiple clinical programs across our hematology and genetic disease portfolio. We are excited to welcome him to the team as we continue to build on our momentum and work to create lasting impact for patients."

    "Beam's mission to transform the treatment of genetic diseases with precision medicines is both inspiring and urgent. I am honored to join a company at the forefront of scientific innovation, especially as it advances a robust clinical pipeline with the potential to make a profound difference in patients' lives," said Mr. Emany. "With a strong financial foundation and a period of significant opportunity ahead, Beam is poised to drive meaningful progress in its pioneering clinical pipeline and differentiated base editing platform. I look forward to contributing to the company's success and helping ensure we have the resources to deliver life-changing therapies to patients worldwide."

    Prior to joining Ironwood, Mr. Emany served as corporate vice president, commercial excellence and chief strategy officer of Integra LifeSciences Holdings Corporation, a publicly held global healthcare company, and as vice president of strategy, treasury and investor relations before that. Prior to Integra, Mr. Emany served in various mergers and acquisitions investment banking roles in Bank of America and BofA Securities, formerly Bank of America Merrill Lynch, for nearly a decade, culminating in his service as managing director in the mergers and acquisitions group, where he led numerous mergers and acquisitions in the healthcare sector. He also served in various other financial roles, including with Goldman Sachs Group and Morgan Stanley. Mr. Emany serves on the board of directors of Assertio Holdings, Inc. (NASDAQ:ASRT). He holds a B.A. in international relations from The Johns Hopkins University and an M.A. in international relations and international economics from The Johns Hopkins School of Advanced International Studies.

    About Beam Therapeutics

    Beam Therapeutics (NASDAQ:BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam's suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including, but not limited to, statements related to: the timing and effective date of the appointment of Mr. Emany; the contributions Mr. Emany may make in his role with the company; the therapeutic applications and potential of our technology, including with respect to ESCAPE; our plans to advance our programs; the sufficiency of our capital resources to fund operating expenses and capital expenditure requirements; and our ability to develop life-long, curative, precision genetic medicines for patients through base editing. Each forward-looking statement is subject to important risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including, without limitation, risks and uncertainties related to: our ability to develop, obtain regulatory approval for, and commercialize our product candidates, which may take longer or cost more than planned; our ability to raise additional funding, which may not be available; our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; the uncertainty that our product candidates will receive regulatory approval necessary to initiate human clinical trials; that preclinical testing of our product candidates and preliminary or interim data from preclinical studies and clinical trials may not be predictive of the results or success of ongoing or later clinical trials; that initiation and enrollment of, and anticipated timing to advance, our clinical trials may take longer than expected; that our product candidates or the delivery modalities we rely on to administer them may cause serious adverse events; that our product candidates may experience manufacturing or supply interruptions or failures; risks related to competitive products; and the other risks and uncertainties identified under the headings "Risk Factors Summary" and "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, and in any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.

    Contacts:

    Investors:

    Holly Manning

    Beam Therapeutics

    [email protected]

    Media:

    Dan Budwick

    1AB

    [email protected]



    Primary Logo

    Get the next $ASRT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Q&A

    New
    • Who has been appointed as the new CFO of Beam Therapeutics and when will they assume the role?

      Beam Therapeutics has appointed Sravan K. Emany as their new CFO effective December 19, 2024. Emany was previously the CFO and COO at Ironwood Pharmaceuticals.

    • What prior experience does Sravan K. Emany have before joining Beam Therapeutics?

      Emany brings extensive experience in finance and operations from various roles, including as CFO at Ironwood Pharmaceuticals and in investment banking at Bank of America Merrill Lynch.

    • What did CEO John Evans say about Sravan Emany's qualifications for the CFO position?

      John Evans, the CEO of Beam, stated that Emany's background and understanding of value creation in life sciences make him an excellent choice to lead Beam's capital formation and allocation strategy.

    • What is the mission of Beam Therapeutics and what technology do they utilize?

      Beam Therapeutics focuses on precision genetic medicines and aims to advance multiple clinical programs across hematology and genetic diseases using their proprietary base editing technology.

    • What types of statements does the press release include that may involve risk and uncertainty?

      The press release contains forward-looking statements concerning the timing and effectiveness of Emany's appointment, the potential of Beam's technology, and their plans for capital resources and clinical trials.

    Recent Analyst Ratings for
    $ASRT
    $BEAM

    CompanyDatePrice TargetRatingAnalyst
    Beam Therapeutics Inc.
    $BEAM
    3/28/2025$42.00Neutral → Buy
    BofA Securities
    Beam Therapeutics Inc.
    $BEAM
    3/10/2025$40.00Sector Perform → Sector Outperform
    Scotiabank
    Beam Therapeutics Inc.
    $BEAM
    1/29/2025Neutral → Overweight
    Cantor Fitzgerald
    Beam Therapeutics Inc.
    $BEAM
    11/6/2024$27.00 → $39.00Market Perform → Outperform
    Leerink Partners
    Beam Therapeutics Inc.
    $BEAM
    10/16/2024Sector Outperform
    Scotiabank
    Assertio Holdings Inc.
    $ASRT
    7/26/2024$3.00Buy
    Maxim Group
    Beam Therapeutics Inc.
    $BEAM
    7/23/2024$80.00Buy
    H.C. Wainwright
    Assertio Holdings Inc.
    $ASRT
    7/3/2024$4.00Buy
    H.C. Wainwright
    More analyst ratings

    $ASRT
    $BEAM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

      Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to <40%, and Resolution of Anemia Patients Required a Median of One Mobilization Cycle and Experienced Rapid Neutrophil and Platelet Engraftment Safety Profile Remained Consistent with Busulfan Conditioning, Autologous Hematopoietic Stem Cell Transplantation and Underlying SCD Enrollment Complete in Both Adult and Adolescent Cohorts of the BEACON Trial, with 30 Patients Expected to be Dosed by Mid-2025 Beam to Host Investor Webcast Today, June 13, 2025, at 4:00 p.m. ET CAMBRIDGE, Mass., June 13, 2025 (GL

      6/13/25 7:00:00 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

      CAMBRIDGE, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to BEAM-101, an investigational genetically modified cell therapy for the treatment of sickle cell disease (SCD). "Sickle cell disease is a devasting disorder that affects approximately 100,000 people in the U.S., leading to anemia, severe pain, stroke and even early death. Receiving orphan drug designation from the FDA emphasizes the importance of new treatment options for this debilitating disease, a

      6/3/25 7:00:00 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

      CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to BEAM-302, a liver-targeting lipid-nanoparticle (LNP) formulation of a guide RNA and an mRNA encoding a base editor designed to correct the disease-causing mutation in patients with alpha-1 antitrypsin deficiency (AATD). AATD is an inherited genetic disorder that affects the lungs and/or liver, leading to early onset emphysema and liver disease, and for which there is significant unmet need for effecti

      5/29/25 4:01:00 PM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ASRT
    $BEAM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Simon Amy sold $23,962 worth of shares (1,250 units at $19.17), decreasing direct ownership by 2% to 64,864 units (SEC Form 4)

      4 - Beam Therapeutics Inc. (0001745999) (Issuer)

      7/3/25 5:30:05 PM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Walsh Kathleen E

      4 - Beam Therapeutics Inc. (0001745999) (Issuer)

      6/6/25 4:05:30 PM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Shaw Christi

      4 - Beam Therapeutics Inc. (0001745999) (Issuer)

      6/6/25 4:05:26 PM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ASRT
    $BEAM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Beam Therapeutics upgraded by BofA Securities with a new price target

      BofA Securities upgraded Beam Therapeutics from Neutral to Buy and set a new price target of $42.00

      3/28/25 8:10:19 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Beam Therapeutics upgraded by Scotiabank with a new price target

      Scotiabank upgraded Beam Therapeutics from Sector Perform to Sector Outperform and set a new price target of $40.00

      3/10/25 11:54:09 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Beam Therapeutics upgraded by Cantor Fitzgerald

      Cantor Fitzgerald upgraded Beam Therapeutics from Neutral to Overweight

      1/29/25 7:35:38 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ASRT
    $BEAM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mason Heather L bought $60,000 worth of shares (75,000 units at $0.80), increasing direct ownership by 35% to 287,650 units (SEC Form 4)

      4 - Assertio Holdings, Inc. (0001808665) (Issuer)

      11/19/24 9:02:18 AM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO O'Grady Brendan P. bought $9,950 worth of shares (11,706 units at $0.85) (SEC Form 4)

      4 - Assertio Holdings, Inc. (0001808665) (Issuer)

      11/15/24 2:43:25 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Vacirca Jeff L bought $11,100 worth of shares (10,000 units at $1.11), increasing direct ownership by 7% to 151,159 units (SEC Form 4)

      4 - Assertio Holdings, Inc. (0001808665) (Issuer)

      6/12/24 6:00:09 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASRT
    $BEAM
    SEC Filings

    See more
    • Beam Therapeutics Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities

      8-K - Beam Therapeutics Inc. (0001745999) (Filer)

      7/3/25 4:30:15 PM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Beam Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Beam Therapeutics Inc. (0001745999) (Filer)

      6/6/25 4:05:16 PM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by Assertio Holdings Inc.

      S-8 - Assertio Holdings, Inc. (0001808665) (Filer)

      5/19/25 4:18:53 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASRT
    $BEAM
    Leadership Updates

    Live Leadership Updates

    See more
    • Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors

      LAKE FOREST, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced today that Mark Reisenauer has been appointed as an independent director to the Company's Board of Directors. Mr. Reisenauer will serve as a member of the Compensation Committee. "Mark is a highly accomplished commercial leader in complex, competitive therapeutic areas who also brings extensive oncology and hematology product experience to our board," said Heather Mason, Chair of Assertio. "His successful new product and indication launches have b

      12/17/24 8:30:00 AM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assertio Holdings, Inc. Appoints Paul Schwichtenberg to New CTO Role, Mary Pietryga as CCO

      LAKE FOREST, Ill., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced today the creation of a new Transformation Office and the appointment of Paul Schwichtenberg as Chief Transformation Officer (CTO). Mr. Schwichtenberg currently serves as the company's Chief Commercial Officer and was previously CFO. "As CTO, Paul will be future looking, working closely with me, to identify synergies, innovative strategies, and new revenue streams to best position the company for future growth," said Brendan O'Grady, Chief Executi

      12/12/24 8:00:00 AM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

      CAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Sravan K. Emany as chief financial officer (CFO), effective December 19, 2024. Mr. Emany brings to Beam a breadth of global operational, commercial and financial experience with multinational public corporations and financial institutions. He most recently served as CFO and chief operating officer at Ironwood Pharmaceuticals, Inc. "Beam has built a strong financial position to advance our portfolio of genetic medicines, and Sravan has an exceptional background to lead our capital fo

      12/6/24 7:00:00 AM ET
      $ASRT
      $BEAM
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $ASRT
    $BEAM
    Financials

    Live finance-specific insights

    See more
    • Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

      Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to <40%, and Resolution of Anemia Patients Required a Median of One Mobilization Cycle and Experienced Rapid Neutrophil and Platelet Engraftment Safety Profile Remained Consistent with Busulfan Conditioning, Autologous Hematopoietic Stem Cell Transplantation and Underlying SCD Enrollment Complete in Both Adult and Adolescent Cohorts of the BEACON Trial, with 30 Patients Expected to be Dosed by Mid-2025 Beam to Host Investor Webcast Today, June 13, 2025, at 4:00 p.m. ET CAMBRIDGE, Mass., June 13, 2025 (GL

      6/13/25 7:00:00 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

      Presentation to Include Updated Data from 17 Sickle Cell Disease Patients in the Ongoing BEACON Phase 1/2 Clinical Trial Evaluating Safety and Efficacy of BEAM-101 Beam to Host Investor Webcast on Friday, June 13, 2025, at 4:00 p.m. ET CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present new data from the BEACON Phase 1/2 clinical trial of BEAM-101 in sickle cell disease (SCD) at the European Hematology Association 2025 Congress (EHA2025), taking place June 12-15, 2025, in Milan, Italy. BEAM-101 is an investigational ge

      5/14/25 9:30:00 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Assertio Holdings, Inc. to Report First Quarter 2025 Financial Results on May 12, 2025

      LAKE FOREST, Ill., May 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that it will release first quarter 2025 financial results on Monday, May 12, 2025, after the market close. Additionally, Assertio's management will host a live webcast conference call at 4:30 p.m. Eastern Time to discuss the financial results and update the Company's 2025 strategic plans. To access the live webcast, conference call information, and other materials, please visit Assertio's investor relations website at http://investor.assertiotx.com/overview/default.aspx. Please connect at least 10 minutes prior to the live webcast to ensure adequate tim

      5/5/25 8:15:00 AM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASRT
    $BEAM
    Insider purchases explained

    Analytical look into recent insider purchases

    See more
    • Insider Analysis: Purchase at Assertio Holdings Inc. on Jun 6

      Recent insider transactions at Assertio Holdings Inc. have brought attention to the company's stock activity. On June 6, 2024, Mason Heather L purchased $24,250 worth of shares, acquiring 25,000 units at $0.97 per share. This transaction increased Mason Heather L's direct ownership by 13% to 212,650 units, as reported in the SEC Form 4. Several other notable insider transactions have taken place at Assertio Holdings Inc. leading up to this purchase. Patel Ajay, Schwichtenberg Paul, and Schlessinger Sam all converted options into shares and covered exercise/tax liability by utilizing their shares. These transactions resulted in ownership increases of 16%, 20%, and 21%, respectively. Addition

      6/10/24 1:20:50 AM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASRT
    $BEAM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Assertio Holdings Inc.

      SC 13G/A - Assertio Holdings, Inc. (0001808665) (Subject)

      11/14/24 3:52:50 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Assertio Holdings Inc.

      SC 13G/A - Assertio Holdings, Inc. (0001808665) (Subject)

      11/12/24 1:34:28 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Beam Therapeutics Inc.

      SC 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)

      11/12/24 9:50:15 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care